What is an Optic Pathway Glioma
Optic pathway glioma (OPG) is a low-grade glioma that develops along the visual pathway, including the optic nerves, optic chiasm, and optic tracts. Although these tumours are slow-growing, their behaviour can be unpredictable. In some patients, the tumour may remain stable for years, while in others it may grow rapidly and lead to vision loss. These tumours arise from astrocytes, a type of glial cell found within the optic nerve and visual pathway. These tumours commonly affect children, usually under 10 years of age, although they can rarely occur in adults.
OPG may occur sporadically, meaning without a known genetic cause, or it may develop in association with mutations in the neurofibromatosis type 1 (NF1) gene. Mutations in the NF1 gene lead to dysfunction of the tumour suppressor protein neurofibromin, which can promote tumour growth. Tumours associated with NF1 often behave differently from sporadic OPGs, which can influence treatment decisions, tumour growth patterns, and long-term outcomes.
Types of Optic Pathway Glioma
Optic pathway gliomas are commonly classified according to where they develop along the visual pathway. Some tumours are confined to one or both optic nerves, while others involve the optic chiasm, optic tracts, or nearby hypothalamic structures.
Tumours involving the optic chiasm may extend into nearby structures such as the hypothalamus or third ventricle, which can increase the risk of hormonal, visual and neurological complications. The location of the tumour often influences both the symptoms experienced and the treatment approach recommended by the healthcare team.
Optic Pathway Glioma Symptoms
Symptoms of OPG depend largely on where the tumour develops and how far it extends along the visual pathway. Tumours affecting the optic nerve may cause different symptoms from those involving the optic chiasm, but both can significantly affect vision and nearby brain structures.
Because OPGs are strongly associated with NF1, children with NF1 are usually advised to undergo regular ophthalmologic assessments throughout childhood to help detect vision changes early. Early screening can help detect tumours before significant vision loss occurs.
Symptoms to watch for include:
- Headaches, often caused by increased pressure inside the skull
- Nausea and vomiting, particularly when associated with increased pressure inside the skull
- Reduced vision or loss of visual acuity
- Eye misalignment (strabismus)
- Proptosis, or bulging of the eye from the eye socket, particularly when the tumour involves the optic nerve within the orbit
- Hormonal problems if the tumour extends into the hypothalamic–pituitary region, including early (precocious) puberty
Early recognition of these symptoms and timely medical evaluation can help preserve vision and improve long-term outcomes.
How Is Optic Pathway Glioma Diagnosed?
Doctors diagnose OPG using a combination of brain imaging (e.g., MRI) and clinical eye examinations. Biopsy is rarely required because OPGs often have characteristic imaging features, and obtaining tissue may carry a risk of damaging the visual pathway.
MRI is the preferred imaging test because it provides detailed views of the optic nerves, optic chiasm, optic tracts, hypothalamus, and surrounding brain structures. MRI can help doctors determine how far the tumour extends along the visual pathway and whether nearby structures are involved.
In rare cases where doctors perform a biopsy, pathologists examine the tissue to confirm the tumour type and assess molecular features that may guide treatment. This helps predict how likely the tumour is to grow and guides treatment decisions.
Doctors also perform detailed vision and neurological assessments to understand the extent of visual impairment. These examinations help determine which treatment approach is most appropriate and how urgently treatment should begin.
Living With Optic Pathway Glioma
OPG’s are relatively rare tumours and often have a favourable overall survival rate.
However, because they affect the visual pathway, patients may continue to face challenges after treatment, including long-term vision changes, hormonal imbalances, and the need for ongoing monitoring. Some patients may also require ongoing treatment to help control tumour growth stable over time.
Treatment during early childhood, particularly prolonged therapy, can affect development, learning, emotional well-being and neurocognitive function. Vision loss, ranging from mild to severe, may occur as a result of either the tumour itself or its treatment and can significantly affect daily life and independence.
When the tumour extends into the hypothalamus, patients may develop hormonal deficiencies. Early diagnosis and hormone replacement therapy can help manage these symptoms and reduce their long-term impact on health and quality of life.
For patients with vision loss in one eye, education and support around living with monocular vision can help them adapt more confidently to daily activities.
Importantly, patients and their families do not face this journey alone. A multidisciplinary team, including oncologists, ophthalmologists and endocrinologists works together to manage vision changes, hormonal problems, and other long-term effects of the disease and its treatment.
Optic Pathway Glioma Treatment and Management Options
Treatment for OPG depends on several factors, including the patient’s age, the tumour’s location, and visual function. Children who do not yet have symptoms are often monitored closely with regular follow-up rather than treated immediately.
For tumours that continue to grow or cause worsening symptoms, chemotherapy is usually the first-line treatment. Doctors typically identify disease progression through MRI scans or gradual loss of vision. The most commonly used chemotherapy regimen includes vincristine and carboplatin. Other treatments, including targeted therapies and alternative chemotherapy regimens, may be considered depending on the tumour’s behaviour and molecular features.
Surgery may be considered to relieve hydrocephalus, obtain tissue for diagnosis in selected cases, or manage specific complications. Because optic nerve gliomas are often diagnosed in young children, doctors generally try to avoid or delay radiotherapy due to its potential long-term side effects on the developing brain. However, radiotherapy may be considered if chemotherapy no longer controls the tumour growth.
In many patients, chemotherapy provides good tumour control, so doctors generally reserve radiotherapy as a salvage or later-line treatment option. When radiotherapy is required, highly conformal techniques such as fractionated external-beam radiotherapy are commonly used to minimise radiation exposure to surrounding healthy tissue.
Optic pathway gliomas most commonly affect children, meaning support extends beyond medical care to include development, education, and long-term wellbeing.
For families, this can involve navigating vision loss, ongoing monitoring, and the emotional impact of a childhood diagnosis, particularly where conditions like NF1 are involved.
Support is available to help you manage both the practical and emotional aspects of care. The National Advocacy Service can assist with accessing NDIS and other support services following an optic nerve glioma diagnosis. You can also visit our Support Hub for resources tailored to parents and families.
References
- Huang M, Patel J, Gasalberti DP, et al. Optic Nerve Glioma. [Updated 2024 Mar 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan.
- Avery, R. A., & Hardy, K. K. (2014, 2014/01/01). Vision specific quality of life in children with optic pathway gliomas. Journal of Neuro-Oncology, 116(2), 341-347. https://doi.org/10.1007/s11060-013-1300-6
- Cassina, M, Frizziero, L, Opocher, E, Parrozzani, R, Sorrentino, U, Viscardi, E, et al. 2019, ‘Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations’, Cancers, vol. 11, no. 11, article 1790.
- Farazdaghi, M. K., Katowitz, W. R., & Avery, R. A. (2019). Current treatment of optic nerve gliomas. Current Opinion in Ophthalmology, 30(5). https://journals.lww.com/co-ophthalmology/fulltext/2019/09000/current_treatment_of_optic_nerve_gliomas.12.aspx
- Fisher, MJ, Avery, RA & Liu, GT 2011, ‘Optic pathway gliomas’, Journal of Neuro-Ophthalmology, vol. 31, no. 3, pp. 269–278.
- Maheshwari, A, Broniscer, A & Fangusaro, J 2022, ‘Novel treatments in optic pathway gliomas’, Frontiers in Ophthalmology, vol. 2.
- Miller, N. R. (2016). Optic Gliomas: Past, Present, and Future. Journal of Neuro-Ophthalmology, 36(4). https://journals.lww.com/jneuro-ophthalmology/fulltext/2016/12000/optic_gliomas__past,_present,_and_future.19.aspx
- Nair, A. G., Pathak, R. S., Iyer, V. R., & Gandhi, R. A. (2014, 2014/08/01). Optic nerve glioma: an update. International Ophthalmology, 34(4), 999-1005. https://doi.org/10.1007/s10792-014-9942-8
- Thomas, R. P., Gibbs, I. C., Xu, L. W., & Recht, L. (2015, 2015/01/27). Treatment Options for Optic Pathway Gliomas. Current Treatment Options in Neurology, 17(2), 2. https://doi.org/10.1007/s11940-014-0333-2